新型磷结合剂碳酸司维拉姆临床应用

Clinical Application of Sevelamer Carbonate, a New Phosphate Binder

碳酸司维拉姆作为一种不吸收的非钙、非金属的磷结合剂,临床用于控制正在接受透析治疗的慢性肾脏病成人患者的高磷血症,目前已在40多国上市并广泛使用。本文通过对碳酸司维拉姆进行文献检索,并对其作用机制、药效学、药动学、临床评价、适应证及药品相关不良反应等进行综述。

Sevelamer carbonate, as a non-absorbed, non-calcium, non-metallic phosphate binder, was approved by FDA for controlling hyperphosphatemia in adult patients with chronic kidney disease undergoing dialysis in October, 2007. Now, the product has been widely used in more than 40 countries. Literature search about sevelamer carbonate was conducted and the mechanism of action, pharmacodynamics, pharmacokinetics, clinical evaluation, indications and adverse reactions of sevelamer carbonate were introduced.